메뉴 건너뛰기




Volumn 30, Issue 33, 2012, Pages 4161-4167

Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: Evidence of clinical and biologic activity in multiple lymphoma subtypes

Author keywords

[No Author keywords available]

Indexed keywords

CD135 ANTIGEN; FLT3 LIGAND; JANUS KINASE 2; JANUS KINASE 2 INHIBITOR; PACRITINIB; STAT3 PROTEIN; STAT5 PROTEIN;

EID: 84869401524     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.42.5223     Document Type: Article
Times cited : (118)

References (32)
  • 2
    • 84860630975 scopus 로고    scopus 로고
    • Targeting the interleukin-6/Jak/stat pathway in human malignancies
    • Sansone P, Bromberg J: Targeting the interleukin-6/Jak/stat pathway in human malignancies. J Clin Oncol 30:1005-1014, 2012
    • (2012) J Clin Oncol , vol.30 , pp. 1005-1014
    • Sansone, P.1    Bromberg, J.2
  • 3
    • 84860238507 scopus 로고    scopus 로고
    • Dynamics and non-canonical aspects of JAK/STAT signalling
    • Mohr A, Chatain N, Domoszlai T, et al: Dynamics and non-canonical aspects of JAK/STAT signalling. Eur J Cell Biol 91:524-532, 2011
    • (2011) Eur J Cell Biol , vol.91 , pp. 524-532
    • Mohr, A.1    Chatain, N.2    Domoszlai, T.3
  • 4
    • 33847351136 scopus 로고    scopus 로고
    • The JAK-STAT signaling pathway: Input and output integration
    • Murray PJ: The JAK-STAT signaling pathway: Input and output integration. J Immunol 178:2623-2629, 2007
    • (2007) J Immunol , vol.178 , pp. 2623-2629
    • Murray, P.J.1
  • 5
    • 38949165127 scopus 로고    scopus 로고
    • Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas
    • Ding BB, Yu JJ, Yu RY, et al: Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas. Blood 111:1515-1523, 2008
    • (2008) Blood , vol.111 , pp. 1515-1523
    • Ding, B.B.1    Yu, J.J.2    Yu, R.Y.3
  • 6
    • 20844433035 scopus 로고    scopus 로고
    • STAT3 is essential for Hodgkin lymphoma cell proliferation and is a target of tyrphostin AG17 which confers sensitization for apoptosis
    • Holtick U, Vockerodt M, Pinkert D, et al: STAT3 is essential for Hodgkin lymphoma cell proliferation and is a target of tyrphostin AG17 which confers sensitization for apoptosis. Leukemia 19:936-944, 2005
    • (2005) Leukemia , vol.19 , pp. 936-944
    • Holtick, U.1    Vockerodt, M.2    Pinkert, D.3
  • 7
    • 78049370405 scopus 로고    scopus 로고
    • Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma
    • Green MR, Monti S, Rodig SJ, et al: Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 116:3268-3277, 2010
    • (2010) Blood , vol.116 , pp. 3268-3277
    • Green, M.R.1    Monti, S.2    Rodig, S.J.3
  • 8
    • 43549097394 scopus 로고    scopus 로고
    • Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-κB pathways in subtypes of diffuse large B-cell lymphoma
    • Lam LT, Wright G, Davis RE, et al: Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-κB pathways in subtypes of diffuse large B-cell lymphoma. Blood 111:3701-3713, 2008
    • (2008) Blood , vol.111 , pp. 3701-3713
    • Lam, L.T.1    Wright, G.2    Davis, R.E.3
  • 9
    • 52949090018 scopus 로고    scopus 로고
    • SOCS regulation of the JAK/STAT signalling pathway
    • Croker BA, Kiu H, Nicholson SE: SOCS regulation of the JAK/STAT signalling pathway. Semin Cell Dev Biol 19:414-422, 2008
    • (2008) Semin Cell Dev Biol , vol.19 , pp. 414-422
    • Croker, B.A.1    Kiu, H.2    Nicholson, S.E.3
  • 10
    • 33846903838 scopus 로고    scopus 로고
    • Cytokine receptor signaling through the Jak-Stat-Socs pathway in disease
    • O'Sullivan LA, Liongue C, Lewis RS, et al: Cytokine receptor signaling through the Jak-Stat-Socs pathway in disease. Mol Immunol 44:2497-2506, 2007
    • (2007) Mol Immunol , vol.44 , pp. 2497-2506
    • O'Sullivan, L.A.1    Liongue, C.2    Lewis, R.S.3
  • 11
    • 36148989576 scopus 로고    scopus 로고
    • Somatic hypermutation of SOCS1 in lymphocyte-predominant Hodgkin lymphoma is accompanied by high JAK2 expression and activation of STAT6
    • Mottok A, Renné C, Willenbrock K, et al: Somatic hypermutation of SOCS1 in lymphocyte-predominant Hodgkin lymphoma is accompanied by high JAK2 expression and activation of STAT6. Blood 110:3387-3390, 2007
    • (2007) Blood , vol.110 , pp. 3387-3390
    • Mottok, A.1    Renné, C.2    Willenbrock, K.3
  • 12
    • 33646382121 scopus 로고    scopus 로고
    • Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation
    • Weniger MA, Melzner I, Menz CK, et al: Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation. Oncogene 25:2679-2684, 2006
    • (2006) Oncogene , vol.25 , pp. 2679-2684
    • Weniger, M.A.1    Melzner, I.2    Menz, C.K.3
  • 13
    • 32144453842 scopus 로고    scopus 로고
    • JAK/STAT signal transduction: Regulators and implication in hematological malignancies
    • Valentino L, Pierre J: JAK/STAT signal transduction: Regulators and implication in hematological malignancies. Biochem Pharmacol 71:713-721, 2006
    • (2006) Biochem Pharmacol , vol.71 , pp. 713-721
    • Valentino, L.1    Pierre, J.2
  • 14
    • 15244350510 scopus 로고    scopus 로고
    • Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in the MedB-1 mediastinal lymphoma line
    • Melzner I, Bucur AJ, Brüderlein S, et al: Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in the MedB-1 mediastinal lymphoma line. Blood 105:2535-2542, 2005
    • (2005) Blood , vol.105 , pp. 2535-2542
    • Melzner, I.1    Bucur, A.J.2    Brüderlein, S.3
  • 15
    • 19944432663 scopus 로고    scopus 로고
    • Differential methylation of genes that regulate cytokine signaling in lymphoid and hematopoietic tumors
    • Reddy J, Shivapurkar N, Takahashi T, et al: Differential methylation of genes that regulate cytokine signaling in lymphoid and hematopoietic tumors. Oncogene 24:732-736, 2005
    • (2005) Oncogene , vol.24 , pp. 732-736
    • Reddy, J.1    Shivapurkar, N.2    Takahashi, T.3
  • 16
    • 27144433826 scopus 로고    scopus 로고
    • Methylation silencing of SOCS-3 promotes cell growth and migration by enhancing JAK/STAT and FAK signalings in human hepatocellular carcinoma
    • Niwa Y, Kanda H, Shikauchi Y, et al: Methylation silencing of SOCS-3 promotes cell growth and migration by enhancing JAK/STAT and FAK signalings in human hepatocellular carcinoma. Oncogene 24:6406-6417, 2005
    • (2005) Oncogene , vol.24 , pp. 6406-6417
    • Niwa, Y.1    Kanda, H.2    Shikauchi, Y.3
  • 17
    • 0026465510 scopus 로고
    • Activation of cytokines in Hodgkin's disease
    • Tesch H, Feller AC, Jucker M, et al: Activation of cytokines in Hodgkin's disease. Ann Oncol 4:13-16, 1992
    • (1992) Ann Oncol , vol.4 , pp. 13-16
    • Tesch, H.1    Feller, A.C.2    Jucker, M.3
  • 18
    • 0027421048 scopus 로고
    • Cytokines in malignant lymphomas: Review and prospective evaluation
    • Hsu SM, Waldron JW Jr, Hsu PL, et al: Cytokines in malignant lymphomas: Review and prospective evaluation. Hum Pathol 24:1040-1057, 1993
    • (1993) Hum Pathol , vol.24 , pp. 1040-1057
    • Hsu, S.M.1    Waldron Jr., J.W.2    Hsu, P.L.3
  • 19
    • 79960178510 scopus 로고    scopus 로고
    • Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5, 7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10, 12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphoma
    • William AD, Lee AC, Blanchard S, et al: Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6) .1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphoma. J Med Chem 54:4638-4658, 2011
    • (2011) J Med Chem , vol.54 , pp. 4638-4658
    • William, A.D.1    Lee, A.C.2    Blanchard, S.3
  • 20
    • 80755140046 scopus 로고    scopus 로고
    • SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies
    • Hart S, Goh KC, Novotny-Diermayr V, et al: SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies. Leukemia 25:1751-1759, 2011
    • (2011) Leukemia , vol.25 , pp. 1751-1759
    • Hart, S.1    Goh, K.C.2    Novotny-Diermayr, V.3
  • 21
    • 33947496614 scopus 로고    scopus 로고
    • Revised response criteria for malignant lymphoma
    • Cheson BD, Pfistner B, Juweid ME, et al: Revised response criteria for malignant lymphoma. J Clin Oncol 25:579-586, 2007
    • (2007) J Clin Oncol , vol.25 , pp. 579-586
    • Cheson, B.D.1    Pfistner, B.2    Juweid, M.E.3
  • 22
    • 80054028202 scopus 로고    scopus 로고
    • Long-term outcome of treatment with ruxolitinib in myelofibrosis
    • Tefferi A, Litzow MR, Pardanani A: Long-term outcome of treatment with ruxolitinib in myelofibrosis. N Engl J Med 365:1455-1457, 2011
    • (2011) N Engl J Med , vol.365 , pp. 1455-1457
    • Tefferi, A.1    Litzow, M.R.2    Pardanani, A.3
  • 23
    • 84861216420 scopus 로고    scopus 로고
    • Phase II study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including post-myeloproliferative neoplasm acute myeloid leukemia
    • Eghtedar A, Verstovsek S, Estrov Z, et al: Phase II study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including post-myeloproliferative neoplasm acute myeloid leukemia. Blood 119:4614-4618, 2012
    • (2012) Blood , vol.119 , pp. 4614-4618
    • Eghtedar, A.1    Verstovsek, S.2    Estrov, Z.3
  • 24
    • 84863393110 scopus 로고    scopus 로고
    • A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis
    • Verstovsek S, Mesa RA, Gotlib J, et al: A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 366:799-807, 2012
    • (2012) N Engl J Med , vol.366 , pp. 799-807
    • Verstovsek, S.1    Mesa, R.A.2    Gotlib, J.3
  • 26
    • 34249041983 scopus 로고    scopus 로고
    • Plasma cytokine and soluble receptor signature predicts outcome of patients with classical Hodgkin's lymphoma: A study from the Groupe d'Etude des Lymphomes de l'Adulte
    • Casasnovas RO, Mounier N, Brice P, et al: Plasma cytokine and soluble receptor signature predicts outcome of patients with classical Hodgkin's lymphoma: A study from the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 25:1732-1740, 2007
    • (2007) J Clin Oncol , vol.25 , pp. 1732-1740
    • Casasnovas, R.O.1    Mounier, N.2    Brice, P.3
  • 27
    • 77649297872 scopus 로고    scopus 로고
    • Proangiogenic cytokines produced by non-Hodgkin lymphoma tumor cells induce angiogenesis in infiltrated bone marrow samples
    • Etto LY, Silva MR, Dalboni MA, et al: Proangiogenic cytokines produced by non-Hodgkin lymphoma tumor cells induce angiogenesis in infiltrated bone marrow samples. Leuk Lymphoma 50:1381-1383, 2009
    • (2009) Leuk Lymphoma , vol.50 , pp. 1381-1383
    • Etto, L.Y.1    Silva, M.R.2    Dalboni, M.A.3
  • 28
    • 77955709652 scopus 로고    scopus 로고
    • Circulating cytokines and risk of B-cell non-Hodgkin lymphoma: A prospective study
    • Gu Y, Shore RE, Arslan AA, et al: Circulating cytokines and risk of B-cell non-Hodgkin lymphoma: A prospective study. Cancer Causes Control 21:1323-1333, 2010
    • (2010) Cancer Causes Control , vol.21 , pp. 1323-1333
    • Gu, Y.1    Shore, R.E.2    Arslan, A.A.3
  • 29
    • 79960394814 scopus 로고    scopus 로고
    • Prediagnostic serum levels of cytokines and other immune markers and risk of non-hodgkin lymphoma
    • Purdue MP, Lan Q, Bagni R, et al: Prediagnostic serum levels of cytokines and other immune markers and risk of non-hodgkin lymphoma. Cancer Res 71:4898-4907, 2011
    • (2011) Cancer Res , vol.71 , pp. 4898-4907
    • Purdue, M.P.1    Lan, Q.2    Bagni, R.3
  • 30
    • 0028893151 scopus 로고
    • Clinical implications of cytokine and soluble receptor measurements in patients with newly-diagnosed aggressive non-Hodgkin's lymphoma
    • Stasi R, Zinzani L, Galieni P, et al: Clinical implications of cytokine and soluble receptor measurements in patients with newly-diagnosed aggressive non-Hodgkin's lymphoma. Eur J Haematol 54:9-17, 1995
    • (1995) Eur J Haematol , vol.54 , pp. 9-17
    • Stasi, R.1    Zinzani, L.2    Galieni, P.3
  • 31
    • 0028301226 scopus 로고
    • Growth signaling and JAK2 association mediated by membrane-proximal cytoplasmic regions of prolactin receptors
    • DaSilva L, Howard OM, Rui H, et al: Growth signaling and JAK2 association mediated by membrane-proximal cytoplasmic regions of prolactin receptors. J Biol Chem 269:18267-18270, 1994
    • (1994) J Biol Chem , vol.269 , pp. 18267-18270
    • DaSilva, L.1    Howard, O.M.2    Rui, H.3
  • 32
    • 79951681794 scopus 로고    scopus 로고
    • Assessment of circulating biomarkers for potential pharmacodynamic utility in patients with lymphoma
    • Greystoke A, O'Connor JP, Linton K, et al: Assessment of circulating biomarkers for potential pharmacodynamic utility in patients with lymphoma. Br J Cancer 104:719-725, 2011
    • (2011) Br J Cancer , vol.104 , pp. 719-725
    • Greystoke, A.1    O'Connor, J.P.2    Linton, K.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.